1-20 of 42
Jingqin Luo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4271: A new methodological approach to discovering biomarkers of mammographic breast density using pathway-guided lipid amalgamation

Chongliang Luo, Jingqin Luo, Kayla R. Getz, Myung Sik Jeon, Adetunji T. Toriola
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4271.
https://doi.org/10.1158/1538-7445.AM2023-4271
Published: 04 April 2023
View article titled, Abstract 4271: A new methodological approach to discovering biomarkers of mammographic breast density using pathway-guided lipid amalgamation
Journal Articles

Abstract 3803: The landscape of circular RNAs in metastatic colorectal cancer

Sidi Zhao, Amy Ly, Jacqueline L. Mudd, Emily B. Rozycki, Ghofran Othoum, Jingqin Luo, Ha X. Dang, Ryan C. Fields, Christopher A. Maher
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3803.
https://doi.org/10.1158/1538-7445.AM2023-3803
Published: 04 April 2023
View article titled, Abstract 3803: The landscape of circular RNAs in metastatic colorectal cancer
Journal Articles

Abstract 4173: Lipidome of mammographic breast density in premenopausal women

Kayla R. Getz, Myung S. Jeon, Chongliang Luo, Jingqin Luo, Adetunji T. Toriola
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4173.
https://doi.org/10.1158/1538-7445.AM2023-4173
Published: 04 April 2023
View article titled, Abstract 4173: Lipidome of mammographic breast density in premenopausal women
Journal Articles

Abstract OT3-11-01: TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity

Nusayba A. Bagegni, Isabella Grigsby, Leslie Nehring, Jingqin Luo, Jennifer Powers Carson, David W. Gibson, Meghan Horvath, Katherine K. Clifton, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Lindsay L. Peterson, Ron Bose, Amy Williams, Mattias Bergqvist, Cynthia Ma
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT3-11-01.
https://doi.org/10.1158/1538-7445.SABCS22-OT3-11-01
Published: 01 March 2023
View article titled, Abstract OT3-11-01: TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity
Journal Articles

Abstract P3-06-07: Phase Ib/II study to evaluate safety and tolerability of cabiralizumab in combination with nivolumab and neoadjuvant chemotherapy in patients with localized triple-negative breast cancer

Andrew A. Davis, Leonel Hernandez-Aya, Jingqin Luo, Mateusz Opyrchal, Foluso O. Ademuyiwa, Nusayba A. Bagegni, Katherine K. Clifton, Jill Anderson, Trish Hammerschmidt, Leslie Nehring, David DeNardo, Mark Watson, Rebecca Aft, Cynthia Ma, Katherine Weilbaecher
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-06-07.
https://doi.org/10.1158/1538-7445.SABCS22-P3-06-07
Published: 01 March 2023
View article titled, Abstract P3-06-07: Phase Ib/II study to evaluate safety and tolerability of cabiralizumab in combination with nivolumab and neoadjuvant chemotherapy in patients with localized triple-negative breast cancer
Journal Articles

Abstract PD13-09: PD13-09 Clinical outcomes of patients with HR+ HER2- advanced breast cancer with early progression on CDK4/6 inhibitors

Katherine K. Clifton, Shana N. Thomas, Jingqin Luo, Jing Xi, Nusayba A. Bagegni, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Ron Bose, Katherine Weilbaecher, Whitney L. Hensing, Timothy Pluard, Massimo Cristofanilli, Hyo S. Han, Adam M. Brufsky, Kevin Kalinsky, Shom Goel, Seth A. Wander, Lindsay L. Peterson, Cynthia Ma
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD13-09.
https://doi.org/10.1158/1538-7445.SABCS22-PD13-09
Published: 01 March 2023
View article titled, Abstract PD13-09: PD13-09 Clinical outcomes of patients with HR+ HER2- advanced breast cancer with early progression on CDK4/6 inhibitors
Journal Articles

Abstract PD12-09: PD12-09 Serum Advanced Glycation End-Products are Associated with Breast Cancer Prognosis

Lindsay L. Peterson, Yu Tao, Jingqin Luo, Graham A. Colditz, Yikyung Park, Jennifer A. Ligibel, David Turner
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD12-09.
https://doi.org/10.1158/1538-7445.SABCS22-PD12-09
Published: 01 March 2023
View article titled, Abstract PD12-09: PD12-09 Serum Advanced Glycation End-Products are Associated with Breast Cancer Prognosis
Journal Articles

Abstract P2-07-01: Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6i)

Andrew Davis, Jingqin Luo, Tiantian Zheng, Lu Tan, Amy Wang, Rama Suresh, Foluso Ademuyiwa, Caron Rigden, Timothy Rearden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Pavan K Tandra, Tracy Summa, Brittney Haas, Shana Thomas, Leonel Hernandez-Aya, Lindsay Peterson, Shujun Luo, Bonnie L King, Shidong Jia, Jianjun Yu, Pan Du, Jairam Krishnamurthy, Cynthia X Ma, C Dai
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-07-01.
https://doi.org/10.1158/1538-7445.SABCS21-P2-07-01
Published: 15 February 2022
View article titled, Abstract P2-07-01: Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6<em>i</em>)
Journal Articles

Abstract P3-09-04: Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations

Jing Xi, Kathleen Harnden, Jingqin Luo, Greg S. Call, Elizabeth Mauer, Karyn Ronski, Cynthia X. Ma, Neil Vasan
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P3-09-04.
https://doi.org/10.1158/1538-7445.SABCS21-P3-09-04
Published: 15 February 2022
View article titled, Abstract P3-09-04: Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations
Journal Articles

Abstract GS4-07: The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts

Siri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, Jose A Seoane, Lorraine M King, Tyler Risom, Lunden Simpson, Sujay Vennam, Aziz Khan, Timothy Hardman, Bryan E Harmon, Fergus J Couch, Kristalyn Gallagher, Mark Kilgore, Shi Wei, Angela DeMichele, Tari King, Priscilla F McAuliffe, Julie Nangia, Joanna Lee, Jennifer Tseng, Anna Maria Storniolo, Alastair Thompson, Gaorav Gupta, Robyn Burns, Deborah J Veis, Katherine DeSchryver, Chunfang Zhu, Magdalena Matusiak, Jason Wang, Shirley X Zhu, Jen Tappenden, Daisy Yi Ding, Dadong Zhang, Jingqin Luo, Shu Jiang, Sushama Varma, Cody Straub, Sucheta Srivastava, Christina Curtis, Rob Tibshirani, Robert Michael Angelo, Allison Hall, Kouros Owzar, Kornelia Polyak, Carlo Maley, Jeffrey R Marks, Graham A Colditz, E Shelley Hwang, Robert B West
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS4-07.
https://doi.org/10.1158/1538-7445.SABCS21-GS4-07
Published: 15 February 2022
View article titled, Abstract GS4-07: The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts
Journal Articles

Abstract P2-13-01: Phase 2 study of neoadjuvant palbociclib, letrozole, and trastuzumab in patients with ER+ HER2+ breast cancer (PALTAN)

Foluso O Ademuyiwa, Donald Northfelt, Tracey O'Connor, Ellis Levine, Jingqin Luo, Yu Tao, Jeremy Hoog, Marie Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S Hagemann, Cynthia X Ma
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-01.
https://doi.org/10.1158/1538-7445.SABCS21-P2-13-01
Published: 15 February 2022
View article titled, Abstract P2-13-01: Phase 2 study of neoadjuvant palbociclib, letrozole, and trastuzumab in patients with ER+ HER2+ breast cancer (PALTAN)
Journal Articles

Loss of Long Noncoding RNA NXTAR in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance

Ruchi Ghildiyal, Mithila Sawant, Arun Renganathan, Kiran Mahajan, Eric H. Kim, Jingqin Luo, Ha X. Dang, Christopher A. Maher, Felix Y. Feng, Nupam P. Mahajan
Journal: Cancer Research
Cancer Res (2022) 82 (1): 155–168.
https://doi.org/10.1158/0008-5472.CAN-20-3845
Published: 04 January 2022
View article titled, Loss of Long Noncoding RNA <em>NXTAR</em> in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance
Open the PDF for Loss of Long Noncoding RNA <em>NXTAR</em> in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER

Cynthia X. Ma, Jingqin Luo, Rachel A. Freedman, Timothy Pluard, Julie Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason Jones, Nancy U. Lin, Eric Winer, P. Kelly Marcom, Shana Thomas, Jill Anderson, Brittney Haas, Kimberly M. Hamann, Richard Bryce, Alshad S. Lalani, Lisa Carey, Matthew Goetz, Feng Gao, Gretchen Kimmick, Mark Pegram, Matthew J. Ellis, Ron Bose
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT026.
https://doi.org/10.1158/1538-7445.AM2021-CT026
Published: 01 July 2021
View article titled, Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER
Journal Articles

Abstract PS12-02: Safety and efficacy of an alternative schedule of palbociclib (PAL) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) and the utility of serum thymidine kinase 1 (sTK1) activity in predicting PAL response

Jairam Krishnamurthy, Jingqin Luo, Rama Suresh, Foluso Ademuyiwa, Caron Rigden, Timothy Reardon, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Anna Roshal, Pavan Tandra, Mathew Cherian, Tracy Summa, Shana Thomas, Leonel Hernandez-Aya, Mattias Bergqvist, Lindsay Peterson, Cynthia X Ma
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS12-02.
https://doi.org/10.1158/1538-7445.SABCS20-PS12-02
Published: 15 February 2021
View article titled, Abstract PS12-02: Safety and efficacy of an alternative schedule of palbociclib (PAL) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) and the utility of serum thymidine kinase 1 (sTK1) activity in predicting PAL response
Journal Articles

Abstract PS18-07: Association between pathological response and tumor genomic profiling in triple negative breast cancer patients treated with neoadjuvant chemotherapy

Foluso O Ademuyiwa, Jingqin Luo, Bryan Fisk, Gejae Jeffers, Tracy Summa, Isabella Grigsby, Mothaffar Rimawi, Meenakshi Anurag, Matthew Ellis, Obi Griffith, Malachi Griffith
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS18-07.
https://doi.org/10.1158/1538-7445.SABCS20-PS18-07
Published: 15 February 2021
View article titled, Abstract PS18-07: Association between pathological response and tumor genomic profiling in triple negative breast cancer patients treated with neoadjuvant chemotherapy
Journal Articles

Abstract PD5-08: The human tumor atlas network (HTAN) breast pre cancer atlas: A multi-omic integrative analysis of ductal carcinoma in situ (DCIS) and correlation with clinical outcomes

Shelley Hwang, Siri H Strand, Belen Rivero, Lorraine King, Tyler Risom, Bryan Harmon, Fergus Couch, Kristalyn Gallagher, Mark Kilgore, Shi Wei, Angela DeMichele, Tari King, Priscilla McAuliffe, Julie Nangia, Ana Maria Storniolo, Alastair Thompson, Gaorav Gupta, Joanna Lee, Jennifer Tseng, Robyn Burns, ChunFang Zhu, Magda Matusiak, Shirley X Zhu, Jason Wang, Jose Seoane, Jen Tappenden, Daisy Ding, Dadong Zhang, Jingqin Luo, Sujay Vennam, Sushama Varma, Lunden Simpson, Luis Cisneros, Timmothy Hardman, Lauren Anderson, Cody Straub, Sucheta Srivastava, Deb J Veis, Christina Curtis, Rob Tibshirani, Robert Michael Angelo, Allison Hall, Kouros Owzar, Kornelia Polyak, Carlo Maley, Jeff Marks, Graham Colditz, Robert B West
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD5-08.
https://doi.org/10.1158/1538-7445.SABCS20-PD5-08
Published: 15 February 2021
View article titled, Abstract PD5-08: The human tumor atlas network (HTAN) breast pre cancer atlas: A multi-omic integrative analysis of ductal carcinoma in situ (DCIS) and correlation with clinical outcomes
Journal Articles

Abstract PS2-09: Next generation sequencing (NGS) in older adults with breast cancer using tissue-based and circulating tumor DNA (ctDNA) assays

Katherine K Clifton, Jingqin Luo, Yu Tao, Jennifer Saam, Thereasa Rich, Timothy Rearden, Anna Roshal, Ashley Frith, Caron Rigden, Foluso Ademuyiwa, Katherine Weilbaecher, Leonel Hernandez Aya, Lindsay Peterson, Nusayba Bagegni, Rama Suresh, Ron Bose, Tanya Wildes, Mateusz Opyrchal, Cynthia Ma
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS2-09.
https://doi.org/10.1158/1538-7445.SABCS20-PS2-09
Published: 15 February 2021
View article titled, Abstract PS2-09: Next generation sequencing (NGS) in older adults with breast cancer using tissue-based and circulating tumor DNA (ctDNA) assays
Journal Articles

Abstract PS4-13: Irreversible inhibition of HER2 activating mutations with neratinib enhances the pre-clinical efficacy of trastuzumab emtansine and trastuzumab deruxtecan

Ron Bose, Shunqiang Li, Tina M. Primeau, Maureen K. Highkin, Ashley R. Tipton, Nagalaxmi Vemalapally, Xuefeng Gao, Gail Sudlow, Irmina Diala, Yu Tao, Jingqin Luo, Ian Hagemann, Chieh-Yu Lin, Richard P. Bryce, Alshad S. Lalani, Samuel Achilefu, Cynthia X. Ma
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS4-13.
https://doi.org/10.1158/1538-7445.SABCS20-PS4-13
Published: 15 February 2021
View article titled, Abstract PS4-13: Irreversible inhibition of HER2 activating mutations with neratinib enhances the pre-clinical efficacy of trastuzumab emtansine and trastuzumab deruxtecan
Journal Articles

Abstract LB-269: Detection of cell-free DNA alterations in AR and its enhancer significantly outperformed CTC AR-V7 detection for identifying treatment resistance in patients with metastatic prostate cancer

Pradeep S. Chauhan, Ha X. Dang, Haley Ellis, Wenjia Feng, Peter K. Harris, Grace Smith, Mark Qiao, Katherine Dienstbach, Rachel Beck, Andrew Atkocius, Faridi Qaium, Jingqin Luo, Jeff M. Michalski, Joel Picus, Russell K. Pachynski, Christopher A. Maher, Aadel A. Chaudhuri
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): LB-269.
https://doi.org/10.1158/1538-7445.AM2020-LB-269
Published: 15 August 2020
View article titled, Abstract LB-269: Detection of cell-free DNA alterations in AR and its enhancer significantly outperformed CTC AR-V7 detection for identifying treatment resistance in patients with metastatic prostate cancer
Journal Articles

Abstract P2-16-03: Neoadjuvant treatment of triple negative breast cancer patients with docetaxel and carboplatin to assess anti-tumor activity

FOLUSO O ADEMUYIWA, Mothaffar F Rimawi, Tracy Summa, Jingqin Luo, Tao Wang, Rama Suresh, Lindsay Peterson, Michael Naughton, Ashley Frith, Leonel Hernandez-Aya, Katherine Weilbaecher, Cynthia Ma, Aadel A Chaudhuri, Yang-Yang Feng, Zachary L Skidmore, Obi L Griffith, Malachi Griffith, Matthew Ellis
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P2-16-03.
https://doi.org/10.1158/1538-7445.SABCS19-P2-16-03
Published: 15 February 2020
View article titled, Abstract P2-16-03: Neoadjuvant treatment of triple negative breast cancer patients with docetaxel and carboplatin to assess anti-tumor activity